the effectiveness of buserelin ( hoechst-roussel pharmaceuticals , inc. , somerville , nj ) ( 0.2 mg subcutaneously [ sc ] or 1.2 mg intranasally [ in ] per day ) and danazol ( 800 mg per day ) in inducing ovarian suppression for the management of endometriosis was compared in a prospective randomized study .
C0010961
danazol
C0014175
endometriosis